Literature DB >> 24183269

Role of minimally invasive surgery in ovarian cancer.

Farr R Nezhat1, Tanja Pejovic, Tamara N Finger, Susan S Khalil.   

Abstract

The standard treatment of ovarian cancer includes upfront surgery with intent to accurately diagnose and stage the disease and to perform maximal cytoreduction, followed by chemotherapy in most cases. Surgical staging of ovarian cancer traditionally has included exploratory laparotomy with peritoneal washings, hysterectomy, salpingo-oophorectomy, omentectomy, multiple peritoneal biopsies, and possible pelvic and para-aortic lymphadenectomy. In the early 1990s, pioneers in laparoscopic surgery used minimally invasive techniques to treat gynecologic cancers, including laparoscopic staging of early ovarian cancer and primary and secondary cytoreduction in advanced and recurrent disease in selected cases. Since then, the role of minimally invasive surgery in gynecologic oncology has been continually expanding, and today advanced laparoscopic and robotic-assisted laparoscopic techniques are used to evaluate and treat cervical and endometrial cancer. However, the important question about the place of the minimally invasive approach in surgical treatment of ovarian cancer remains to be evaluated and answered. Overall, the potential role of minimally invasive surgery in treatment of ovarian cancer is as follows: i) laparoscopic evaluation, diagnosis, and staging of apparent early ovarian cancer; ii) laparoscopic assessment of feasibility of upfront surgical cytoreduction to no visible disease; iii) laparoscopic debulking of advanced ovarian cancer; iv) laparoscopic reassessment in patients with complete remission after primary treatment; and v) laparoscopic assessment and cytoreduction of recurrent disease. The accurate diagnosis of suspect adnexal masses, the safety and feasibility of this surgical approach in early ovarian cancer, the promise of laparoscopy as the most accurate tool for triaging patients with advanced disease for surgery vs upfront chemotherapy or neoadjuvant chemotherapy, and its potential in treatment of advanced cancer have been documented and therefore should be incorporated in the surgical methods of every gynecologic oncology unit and in the training programs in gynecologic oncology.
Copyright © 2013 AAGL. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cytoreduction; Laparoscopy; Ovarian cancer; Robotic-assisted laparoscopy; Staging

Mesh:

Year:  2013        PMID: 24183269     DOI: 10.1016/j.jmig.2013.04.027

Source DB:  PubMed          Journal:  J Minim Invasive Gynecol        ISSN: 1553-4650            Impact factor:   4.137


  17 in total

1.  Interval robotic cytoreduction following neoadjuvant chemotherapy in advanced ovarian cancer.

Authors:  Sarah A Ackroyd; Sajeena Thomas; Cynthia Angel; Richard Moore; Philip J Meacham; Brent DuBeshter
Journal:  J Robot Surg       Date:  2017-06-19

2.  Impact of robotic surgery on patient flow and resource use intensity in ovarian cancer.

Authors:  Jeremie Abitbol; Beste Kucukyazici; Sonya Brin; Susie Lau; Shannon Salvador; Agnihotram V Ramanakumar; Roy Kessous; Liron Kogan; John D Fletcher; Valerie Pare-Miron; Gilbert Liu; Walter H Gotlieb
Journal:  J Robot Surg       Date:  2022-08-04

3.  Laparoscopic staging for apparent stage I epithelial ovarian cancer.

Authors:  Alexander Melamed; Nancy L Keating; Joel T Clemmer; Amy J Bregar; Jason D Wright; David M Boruta; John O Schorge; Marcela G Del Carmen; J Alejandro Rauh-Hain
Journal:  Am J Obstet Gynecol       Date:  2016-08-25       Impact factor: 8.661

Review 4.  Prediction of anti-angiogenesis escape.

Authors:  Takashi Mitamura; Charlie Gourley; Anil K Sood
Journal:  Gynecol Oncol       Date:  2015-12-31       Impact factor: 5.482

5.  Laparoscopic cytoreduction After Neoadjuvant ChEmotherapy (LANCE).

Authors:  Roni Nitecki; Jose Alejandro Rauh-Hain; Alexander Melamed; Giovanni Scambia; Rene Pareja; Robert L Coleman; Pedro T Ramirez; Anna Fagotti
Journal:  Int J Gynecol Cancer       Date:  2020-07-20       Impact factor: 3.437

Review 6.  Is It the Time for Laparoscopic Management of Early-stage Ovarian Malignancies?

Authors:  Tanitra Tantitamit; Chyi-Long Lee
Journal:  Gynecol Minim Invasive Ther       Date:  2018-08-23

7.  Clinical Availability of Tumour Biopsy Using Diagnostic Laparoscopy for Advanced Ovarian Cancer.

Authors:  Suguru Odajima; Kazu Ueda; Satoshi Hosoya; Keisuke Tomita; Sayako Kato; Yuichi Shoburu; Ayako Kawabata; Yasushi Iida; Nozomu Yanaihara; Aikou Okamoto
Journal:  In Vivo       Date:  2021 Nov-Dec       Impact factor: 2.155

8.  The Role of Minimally Invasive Surgery in the Care of Women with Ovarian Cancer: A Systematic Review and Meta-analysis.

Authors:  Anne Knisely; Charlotte R Gamble; Caryn M St Clair; June Y Hou; Fady Khoury-Collado; Allison A Gockley; Jason D Wright; Alexander Melamed
Journal:  J Minim Invasive Gynecol       Date:  2020-11-14       Impact factor: 4.314

9.  Risk prediction model for epithelial ovarian cancer using molecular markers and clinical characteristics.

Authors:  Meiying Zhang; Guanglei Zhuang; Xiangjun Sun; Yanying Shen; Aimin Zhao; Wen Di
Journal:  J Ovarian Res       Date:  2015-10-21       Impact factor: 4.234

10.  Pelvic mass, ascites, hydrothorax: a malignant or benign condition? Meigs syndrome with high levels of CA 125.

Authors:  Guglielmo Stabile; Giulia Zinicola; Federico Romano; Antonio Simone Laganà; Chiara Dal Pozzolo; Giuseppe Ricci
Journal:  Prz Menopauzalny       Date:  2021-05-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.